Poultry Vaccines Could Reach $5.44 Billion by 2035. Which Companies Are Positioned to Win?

The global poultry vaccines market was estimated at $2.6 billion in 2025 and is projected to reach $5.44 billion by 2035, expanding at a 7.64% CAGR. North America accounted for an estimated 30% of revenue in 2025, according to Towards Healthcare.

But the opportunity goes beyond market growth. Disease control, vaccine innovation, manufacturing capacity and country-specific vaccination policies will determine where companies can compete.

Download Ready to use and Customized Sample: https://www.towardshealthcare.com/download-sample/6528 

Market indicators to watch

Sources: Towards Healthcare; USDA response announcement referenced in the report.

Disease pressure creates a commercial need

The World Organisation for Animal Health reported 1,692 HPAI outbreaks in poultry across 59 countries and territories between January 2024 and May 25, 2025. These reports included 16.24 million poultry cases and 148.68 million poultry losses.

The commercial need also extends beyond avian influenza. Newcastle disease, infectious bronchitis, infectious bursal disease and Marek’s disease require different prevention strategies across production systems.

Competitive landscape

These are strategic areas for competitor monitoring, not a ranking of poultry-vaccine revenue. Public company-wide animal-health revenue should not be mistaken for sales from poultry vaccines alone.

Where can companies find their next opportunity?

• Technology: Recombinant, vector-based and multivalent vaccines, with delivery methods suited to commercial hatcheries.

• Geography: Assess demand across Asia-Pacific, Latin America and other poultry-producing regions, alongside regulatory and disease-control requirements.

• Manufacturing: Evaluate production capacity, cold-chain requirements, supply reliability and local registration.

• Commercial strategy: Identify poultry integrators, hatcheries, veterinary distributors and government procurement opportunities.

Vaccination policy is not uniform across countries. India, for example, reported that its HPAI control policy relies on detection and culling rather than vaccination against highly pathogenic avian influenza. Companies must therefore assess local regulation before treating disease burden as a directly addressable vaccine opportunity.

How Towards Healthcare supports animal-health decision-makers

• Complete Master Dataset: Map companies, products, technologies and regional activity.

• Competitive Quadrant: Benchmark manufacturers and their strategic positioning.

• Customized Dashboard: Track company developments, product portfolios and geographic opportunities.

• Pipeline Intelligence and Buyer Identification: Monitor vaccine development and identify relevant commercial targets.

Explore the company landscape and dataset to identify competitive gaps, target markets and potential partners.

About Us

Healthcare WebWire is part of Towards Healthcare, which is a healthcare intelligence and market research company specializing in market intelligence, competitive intelligence, customer intelligence, pipeline intelligence, market sizing and commercial strategy across pharmaceutical, biotechnology, medical device and healthcare markets.

Contact us for quick meeting, customized data, free samples or further enquiry at [email protected]

Europe Region - +44 778 256 0738

North America Region - +1 8044 4193 44

APAC Region: +91 9356 9282 04

Visit Our Website: https://www.towardshealthcare.com

Find us on social platforms: LinkedIn | Twitter | Instagram | Medium